BATON ROUGE, La., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2021.

Three-Month Periods Ended September 30, 2021 and 2020

• Net service revenue increased $9.4 million to $553.5 million compared to $544.1 million in 2020.
• Net income attributable to Amedisys, Inc. of $45.0 million compared to $72.0 million (inclusive of a $24.0 million income tax benefit related to executive stock option exercise) in 2020.
• Net income attributable to Amedisys, Inc. per diluted share of $1.37 compared to $2.16 (inclusive of $0.72 income tax benefit related to executive stock option exercise) in 2020.

Adjusted Quarterly Results*

• Adjusted EBITDA of $72.4 million compared to $75.7 million in 2020.
• Adjusted net service revenue of $553.5 million compared to $544.1 million in 2020.
• Adjusted net income attributable to Amedisys, Inc. of $50.5 million compared to $74.6 million (inclusive of a $24.0 million income tax benefit related to executive stock option exercise) in 2020.
• Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.53 compared to $2.24 (inclusive of $0.72 income tax benefit related to executive stock option exercise) in 2020.

Nine-Month Periods Ended September 30, 2021 and 2020

• Net service revenue increased $134.0 million to $1,654.8 million compared to $1,520.8 million in 2020.
• Net income attributable to Amedisys, Inc. of $175.0 million compared to $138.5 million (inclusive of a $24.0 million income tax benefit related to executive stock option exercise) in 2020.
• Net income attributable to Amedisys, Inc. per diluted share of $5.30 compared to $4.16 (inclusive of $0.72 income tax benefit related to executive stock option exercise) in 2020.

Adjusted Year to Date Results*

• Adjusted EBITDA of $234.8 million compared to $195.4 million in 2020.
• Adjusted net service revenue of $1,648.3 million compared to $1,520.8 million in 2020.
• Adjusted net income attributable to Amedisys, Inc. of $157.5 million compared to $153.9 million (inclusive of a $24.0 million income tax benefit related to executive stock option exercise) in 2020.
• Adjusted net income attributable to Amedisys, Inc. per diluted share of $4.77 compared to $4.63 (inclusive of $0.72 income tax benefit related to executive stock option exercise) in 2020.

* See pages 3 and 16 - 18 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.

Updated 2021 Guidance

COVID-19 has continued to impact the operating metrics typically used to forecast both growth and cost assumptions for both core Amedisys and Contessa. We are basing our guidance on our current operating environment. COVID-19 continues to evolve in both the disease itself as well as disruptions to the healthcare systems and the economy. Any future regulations or government interventions, spike in clinicians and business development staff on quarantine, staffing shortages due to current and proposed federal, state and local vaccine mandates, reduction in elective procedures, change in patient behavior and further decline in senior living occupancy could impact our ability to achieve this guidance.

Based upon the above discussion, our updated 2021 guidance is as follows:

• Adjusted net service revenue is anticipated to be in the range of $2.200 billion to $2.205 billion.
• Adjusted EBITDA is anticipated to be in the range of $296 million to $298 million.
• Adjusted diluted earnings per share is anticipated to be in the range of $5.88 to $5.93 based on an estimated 33.0 million shares outstanding.

This guidance excludes the effects of any future acquisitions, if any are made.

Paul B. Kusserow, Chairman and Chief Executive Officer stated, “Though COVID-19 continues to impact all of our lines of business, I am very proud of the efforts of the nearly 21,000 Amedisys employees and thank them for their continued dedication and tireless work throughout this quarter and for the results their work produced. Our operating environment continues to change in real-time and yet we have been able to grow Home Health and Hospice admissions. We have made significant progress on recovering our Hospice Business Development staff and remain very confident in our ability to continue to expand this group, translating into further admissions growth. Though it is hard to predict when the impacts of COVID-19 will truly subside, we remain very excited about all of the opportunity ahead of us. We are well positioned to capitalize on the aging demographics of the U.S. population; our industry leading quality scores make us a provider of choice for those that want to be cared for in their homes; and via our acquisition of Contessa, we have assembled a group of assets that truly differentiate Amedisys from our peers. It is a time unlike any other to be in our spaces and tackling the challenges of COVID-19 has, and continues to, energize our entire organization. My enthusiasm for the future of Amedisys has never been stronger.”

We urge caution in considering the current trends and 2021 guidance disclosed in this press release. The home health, hospice, personal care and high acuity care industries are highly competitive and subject to intensive regulations, and trends are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission (“SEC”) including our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC’s internet website, http://www.sec.gov , and our internet website, http://www.amedisys.com . 

Earnings Call and Webcast Information

Amedisys will host a conference call on Wednesday, November 3, 2021, at 11:00 a.m. ET to discuss its third quarter results. To participate on the conference call, please call before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay of the conference call will be available through December 3, 2021 by dialing (877) 660-6853 (Toll-Free) or (201) 612-7415 (Toll) and entering conference ID #13724253.

A live webcast of the call will be accessible through our website on our Investor Relations section at the following web address: http://investors.amedisys.com.

Non-GAAP Financial Measures

This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted net service revenue, defined as net service revenue excluding certain items; (3) adjusted other operating income, defined as other operating income excluding certain items; (4) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. excluding certain items; and (5) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.

Additional Information

Amedisys, Inc. (the “Company”) is a leading healthcare at home company delivering personalized home health, hospice, personal care and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering our patients to manage a chronic disease; or hospice care at the end of life. More than 2,900 hospitals and 78,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 21,000 employees in 527 care centers within 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 418,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com. 

We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

Forward-Looking Statements

When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, the impact of current and proposed federal, state and local vaccine mandates, including potential staff shortages, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except per share data)
(Unaudited)

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING
(Amounts in thousands, except statistical information)
(Unaudited)

(1) Our calculation of days revenue outstanding, net is derived by dividing our ending patient accounts receivable at September 30, 2021 and 2020 by our average daily net patient service revenue for the three-month periods ended September 30, 2021 and 2020, respectively.

AMEDISYS, INC. AND SUBSIDIARIES
SEGMENT INFORMATION
(Amounts in millions, except statistical information)
(Unaudited)

Segment Information - Home Health

(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total volume includes all admissions and recertifications.
(3) Total includes acquisitions, start-ups and denovos.
(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the transition to PDGM effective January 1, 2020 and the suspension of sequestration effective May 1, 2020.
(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
(6) Prior year amounts have been recast to conform to the current year calculation.

Segment Information - Hospice

(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total includes acquisitions, start-ups and denovos.

Segment Information - Personal Care

Segment Information - High Acuity Care

Segment Information - Corporate

AMEDISYS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES
(Amounts in thousands)
(Unaudited)

Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“Adjusted EBITDA”) Reconciliation:

Adjusted Net Service Revenue Reconciliation:

Adjusted Other Operating Income Reconciliation:

Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:

Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:

(1) The following details the certain items for the three and nine-month periods ended September 30, 2021 and 2020:

Certain Items:

(2) Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.
(3) Adjusted net service revenue is defined as net service revenue excluding certain items as described in footnote 1.
(4) Adjusted other operating income is defined as other operating income excluding certain items as described in footnote 1.
(5) Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.
(6) Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.
(7) Adjusted EBITDA, adjusted net service revenue, adjusted other operating income, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.